Seek Labs Joins BioMaP-Consortium to Support U.S. Biomanufacturing Preparedness Efforts

Seek Labs today announced that it has joined the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a national public-private partnership focused on strengthening the United States’ ability to rapidly develop and manufacture critical medical countermeasures.

Supported by the Biomedical Advanced Research and Development Authority (BARDA), the BioMaP-Consortium brings together leaders across the drug and vaccine ecosystem to expand domestic biomanufacturing capacity and improve resilience against future public health threats. The consortium is designed to accelerate the transition from discovery to scalable production of therapeutics, diagnostics, and vaccines.

Seek Labs operates at the earliest stage of disease response, accelerating how quickly disease threats are identified, genomic targets are defined, and countermeasures can be designed before manufacturing begins. The company’s integrated platform combines AI-driven target discovery, molecular detection, and programmable CRISPR therapeutics into a single, unified system. By unifying discovery, detection, and intervention, Seek Labs compresses the time from threat identification to actionable countermeasure design, strengthening readiness and directly supporting BioMaP’s mission to rapidly respond to emerging and engineered biological threats.

BioMaP represents a critical platform to translate Seek Labs’ innovation into real-world impact. Participation in the consortium expands opportunities for federal funding, strategic partnerships, and integration into national preparedness initiatives, reinforcing Seek Labs’ role in advancing rapid-response infrastructure for national health and biodefense.